Redeye provides a research update following the Q1 report recently published by Magle. While narrowly missing our estimates, the company continues to report high sales figures with a substantial y/y growth as Magle Biopolymers and Magle Biopharma are being fully integrated. We remain firm in our belief that the new Magle Group is poised to continue its growth and generate further shareholder value ahead.
LÄS MER
